


**World Dementia
Council** Leading the Global Action
Against Dementia

Global dialogue on technology: Agenda and participants

The dementia landscape
project

4 March 2021





Logistics and agenda

Thursday 4 March 2021


Virtual meeting

08:00 - 09:30 PST San Francisco
10:00 - 11:30 CST Chicago
11:00 - 12:30 EST New York
16:00 - 17:30 GMT London
17:00 - 18:30 CET Central Europe



Section	Speaker(s)
Welcome	Lenny Shallcross
Opening remarks	Jeremy Hughes
Opening presentations	Chaired by Jeremy Hughes
Supporting primary prevention and the early detection of cognitive changes and secondary prevention	Dr Amanda Lazar
Supporting people with dementia to live well, maintain independent function and participate in everyday life	Professor David Sharp
Enabling the better provision of health care	Dr Allison Sekuler
Group conversation	Introduced and moderated by Dr Vaibhav Narayan
Closing perspectives	Jeremy Hughes
Closing thanks	Lenny Shallcross

Co-chairs



Jeremy Hughes CBE

Jeremy Hughes works in health and social care and is former Chief Executive of the Alzheimer’s Society in the UK, where he led the charity in its five-year strategy “The New Deal on Dementia 2017-22”. He chaired the Dementia Technology Working Group for the UK Department of Health & Social Care, and he was awarded the CBE for services to older people in the Queen’s Birthday Honours 2015.




Dr Vaibhav Narayan

Dr Vaibhav Narayan is currently Vice President of Digital Health Innovation, Science for Minds, at Johnson & Johnson (J&J). ‘Science for Minds’ is a newly launched initiative at J&J to address the significant unmet need surrounding neuropsychiatric and neurodegenerative disorders, with a focus on three key areas: 1) serious mental health disorders, especially those impacting adolescents, 2) dementia, and 3) holistic mental health care. Prior to this role, Vaibhav was Head of Data Science for the Neuroscience Therapeutic Area at Janssen, the pharmaceutical division of J&J. In these roles, Vaibhav has led internal programs, industry collaborations and public-private partnerships to discover and validate digital solutions for early detection, disease progression monitoring and relapse prediction in Alzheimer’s, Mood and Schizophrenia. An integral component of this digital and data driven strategy has been ‘disease interception’: i.e., deflecting trajectory of CNS diseases through remote monitoring and early detection and integrated pharmacological/ non-pharmacological solutions that modify disease and develop resilience.



Speakers



Dr Amanda Lazar


Amanda Lazar is an assistant professor in the College of Information Studies at the University of Maryland, College Park. She received her PhD from the University of Washington in the Department of Biomedical Informatics and Medical Education. Her research examines the design of technology for older adults – and in particular, older adults with dementia – to support social interaction and engagement in activities. Her work is supported by the National Science Foundation (NSF) and the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR).



Professor David Sharp

Professor David Sharp is a neurologist and Centre Director of UK DRI Care Research & Technology, focusing on using technology to enhance the lives of people living with dementia. He is also Scientific Director of the Imperial College Clinical Imaging Facility and Associate Director of the Imperial Centre for Injury Studies. His research programme aims to improve clinical outcomes after dementia and traumatic brain injury (TBI), focusing on common cognitive impairments in domains such as memory and attention. He uses cognitive neuroscience and advanced neuroimaging to investigate the effect of brain injury on brain network function and the effects of inflammation and neurodegeneration. His has explored how new treatments of cognitive impairment can be personalised and his current work focuses on harnessing neurotechnology development to improve the lives of those living with dementia and the effects of brain injury.





Dr Allison Sekuler


Dr Allison Sekuler (FSEP, FPS, FAPS) is the Sandra A. Rotman Chair in Cognitive Neuroscience and Vice-President Research at Baycrest Health Sciences, and Managing Director of the Rotman Research Institute and the Centre for Aging + Brain Health Innovation (supporting innovators in Ontario, across Canada, and globally). A graduate of Pomona College (BA, Mathematics and Psychology) and the University of California, Berkeley (PhD, Psychology), Dr Sekuler holds faculty positions in the Department of Psychology, Neuroscience & Behaviour at McMaster University and the Department of Psychology at the University of Toronto. Her research uses behavioural and neuroimaging approaches to understand how the brain processes visual information, with specific interests in face perception, motion processing, perceptual learning, neural plasticity, aging, and neurotechnology. Her research was the first to show conclusively that older brains “rewire” themselves to compensate for functional changes.



Lenny Shallcross

Lenny Shallcross is executive director at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at DCMS and the DoH, as well as working in Parliament and for the Labour Party.





Discussion participants



Professor Dag Aarsland

Professor and Head of Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience at King's College London


Dag Aarsland, MD, is Professor and Head of Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience at King's College London, and Research Director at the Centre for Age-Related Medicine, Stavanger University Hospital. As a psychiatrist he has worked as a senior consultant in geriatric psychiatry for most of his career. His main research interest is the neuropsychiatric aspects of patients with neurodegenerative diseases, in particular translational studies on cognitive decline in Parkinson's disease and dementia with Lewy bodies, and is leading several national and international multi-centre research projects. He is PI of European DLB Consortium, chair of the ISTAART Professional Interest Group for Lewy body dementias and Dementia theme lead of the Maudsley Biomedical Research Centre at KCL. He has published more than 500 papers, including clinical trials, cohort studies, and a wide range of biomarkers including imaging, CSF and EEG, and is among the most cited neuroscientists.



Sofiat Akinola

Global Health and Healthcare & Council Manager, Global Future Council on Healthy Ageing and Longevity, World Economic Forum

Sofiat Akinola is a global health and policy practitioner with extensive experience in strategy implementation. She has experience using evidence to inform policy through systematic research, data analysis, monitoring and evaluation. Sofiat is a Specialist, Global Health and Healthcare at the World Economic Forum working on health systems transformation with a focus on Universal Health Coverage where she leads project on UHC2030 Private-Sector Constituency (UHC2030 PSC). UHC2030 PSC is the convening platform for private sector entities wishing to exchange and collaborate on universal health coverage.



Professor Arlene Astell

Professor in Neurodegenerative Disease in the department of Psychology at the University of Reading


Arlene is a Professor in Neurodegenerative Disease in the department of Psychology at the University of Reading, and Honorary Professor in the School of Psychology & Neuroscience at the University of St. Andrews. She is also Ontario Shores Research Chair in Community Management of Dementia and Associate Professor in the School of Psychiatry at the University of Toronto. For over 20 years Arlene has worked with older adults in both clinical and research settings to develop novel interventions to enable people to live and age as well as possible. Her work includes the creative application of technology and she has a particular interest in supporting people to live well with a dementia diagnosis."



Professor Rhoda Au

Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine

Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine. She also serves as Director of Neuropsychology at the Framingham Heart Study, where she is using technologies to develop digital cognitive biomarkers as surrogate indices of fluid and imaging biomarkers. She also seeks to facilitate development of a multi-sensory brain health monitoring platform that is customizable, flexibly responsive to the rapidly changing technology landscape, technology agnostic, and scalable. Further, she has a priority objective of transitioning from reliance on active engagement technologies to low/no engagement ones and developing methods for identifying and validating novel digital biomarkers. Her long-term objective is to enable solutions that move the primary focus of health technologies from precision medicine to a broader emphasis on precision brain health.



Dr David Bates

CEO and co-founder of
Linus Health


David Bates, PhD, is a scientist, engineer, inventor, entrepreneur and investor. He is the CEO and co-founder of Linus Health, a Boston-based health technology company that offers a digital platform for multimodal brain health assessment and precision care beginning with cognition and motor impairments in seniors. Linus provides both rapid (~2 min) multimodal assessment capabilities at the point of care, as well as a remote, connected 'Ecosystem of Care' model that connects clinicians with patients and their loved ones. He is on the board of several technology companies, as well as the philanthropic TMCity Foundation. David has previously held positions at Morningside Ventures, F-Wave, Harvard Medical School, Massachusetts General Hospital, University of Louisville, and Georgia Tech.



Dr Marco Blom

Scientific director,
Alzheimer Nederland

Marco Blom (1961) is scientific director of Alzheimer Nederland (Alzheimer's Society in the Netherlands). He is psychogerontologist and since 1987 involved in organisations and projects on dementia. He started his career at a Community Mental Health Centre in The Hague and was in 1991 appointed at the National Institute of Care and Welfare (now called Vilans) in Utrecht. In March 1997 he joined Alzheimer Nederland. He was involved in the development of the Alzheimer Cafes, the academic Alzheimer Research Centres and the online platform (www.dementie.nl) for people with dementia and their family caregivers. Other affiliations: board member of the Delta Plan Dementia, the national program on dementia in the Netherlands (2013 – 2020), member of the editorial board of the Netherlands Journal of Psychogeriatrics (called Denkbeeld) and board member of Alzheimer Europe (since 2018).



Dr Guy Boersma

Managing Director of
Kent Surrey Sussex
Academic Health
Science Network


Guy is the Managing Director of Kent Surrey Sussex Academic Health Science Network. He also leads on Digital Innovation and AI for the national AHSN Network. Guy has worked in health and care for more than 20 years, in both private and public sector organisations and at national, regional and local level. He is a collaborative leader, relishing the role of catalysing effective delivery across organisations. In 2019 Guy became a Healthcare Denmark ambassador, which involves helping to connect colleagues in the UK with colleagues in Denmark to foster international collaboration.



Dr Dennis Chan

Principal Research
Fellow at the
Institute of Cognitive
Neuroscience,
University College
London

Dr Dennis Chan is Principal Research Fellow at the Institute of Cognitive Neuroscience, University College London having moved to UCL from the University of Cambridge in 2020. He is a practising neurologist, running memory clinics in South East England, and as well as his medical qualification he holds dual research doctorates in basic and clinical neuroscience, having completed his initial PhD with Nobel Laureate John O’Keefe at UCL. His primary clinical and academic interest is the detection of early Alzheimer’s disease using novel tasks based on hippocampal neuroscience and he has pioneered the use of various tech-based methodologies for AD diagnosis including VR- and app-based tests. In collaboration with Professor O’Keefe he is investigating the effects of AD pathological spread in mouse models of AD, translating outputs from the animal work to the study of at-risk human cohorts. Dr Chan co-leads the digital hub within the Alzheimer’s Research UK Initiative on Early Detection of Neurodegenerative Diseases (EDoN). His work has been published in Nature and The Lancet, among other journals, and he is funded by Alzheimer’s Research UK and the Wellcome Trust.



Melissa Chan

Founder, Project We
Forgot



Melissa Chan is currently working with several health and community care organisations in Asia, including the Alzheimer's Disease Association (ADA) Singapore, and ECON Healthcare Group, to lead service design, innovation, solution development, and growth projects. She was formerly Head of Community and Outreach at Homage, an on-demand technology care solution. Melissa led growth and partnerships with governmental agencies, healthcare institutions, and community partners in Singapore and Malaysia, piloting and launching new initiatives such as Care Experiences, and Home-Based Cognitive Care Assessment Programmes. She is also the founder of Project We Forgot (PWF), a platform for caregivers that provides access to support resources across the dementia care journey. Her experience spans social innovation, service design, growth, marketing, and building brand strategies for the finance, hospitality, travel, and health sectors. Melissa also serves as President for the World Young Leaders in Dementia (WYLD) Network, driving dementia innovation across disciplines and borders."



Dr Liz Coulthard

Associate Professor in
Dementia Neurology,
University of Bristol

I lead the ReMemBr group (Research into Memory, Brain sciences and dementia) comprising neurologists, psychologists and researchers. My main research interest within the group is the effect of neurological disease on cognitive functions, such as decision-making and memory, and the potential for cognitive enhancement in patients as well as early diagnosis and clinical trials in dementia. Current research themes include the role of dopamine in memory consolidation, the effect of subthalamic nucleus stimulation on decision making and the effect of caffeine on attention in people with and without dementia. Translational research is a focus of the ReMemBr group. We see and treat patients with dementia and also offer research opportunities to people with and without dementia including clinical trials of dementia treatment. Collaboration with Professor Risto Kauppinen in CRICBristol is pivotal in developing neuroimaging as a biomarker for dementia diagnosis and monitoring."



Dr Jacqueline Damant

Research Officer,
London School of
Economics


Dr Jacqueline Damant completed a BSc (Nursing) and subsequently, a Bachelor of Commerce at McGill University (Montreal, Canada). After arriving in the UK, she completed an MPhil (Development Studies) at Cambridge University and worked in epidemiological research at University College London. In 2015, she was awarded her PhD which explored the digital inclusion of older adults. Since joining the Care Policy and Evaluation Centre (CPEC) of the LSE in 2004, Dr Damant has worked on projects exploring the use of technology in care, dementia care, personalisation of residential care services and unpaid carers' support. Most recently, she begun work on a project investigating the impact of ICT-use (and non-use) by unpaid carers of people with dementia on their quality of life and that of the people they care for. Jacqueline concurrently works part-time as a Registered Nurse in a community hospital which serves older people with rehabilitation needs, awaiting community care packages.



Dr Michael Devous

Vice President
of Imaging
Development at Avid
Radiopharmaceuticals

Dr Devous is Vice President of Imaging Development at Avid Radiopharmaceuticals. He was previously Professor of Radiology, Neurology, and Bioengineering, Director of the Alzheimer's Disease Center Neuroimaging Core, Co-Principal Investigator of the North Texas Traumatic Brain Injury Model System, and Associate Director of the Nuclear Medicine Center at the University of Texas Southwestern Medical Center, Dallas, Texas. He remains an Adjunct Professor of Neurology at UT Southwestern and of Behavioral and Brain Sciences at the University of Texas at Dallas. He has authored more than 200 peer-reviewed articles, 375 abstracts, and 30 books or book chapters. Dr Devous is past president of the Society of Nuclear Medicine, the Education and Research Foundation, and the Brain Imaging Council. He is a former chair of the Food and Drug Administration Medical Imaging Drugs Advisory Committee. He has received numerous awards, including: Presidential Distinguished Service Award - Society of Nuclear Medicine; Scientific Merit First Award - American Speech, Language and Hearing Association; and the



Kuhl-Lassen Award, the highest award of the Brain Imaging Council and the Society of Nuclear Medicine. His research focuses on advancing understanding of the pathobiology of neurologic and psychiatric disorders, and normal brain function, through molecular, functional, and structural neuroimaging techniques."



Dr Daniel Di Giusto

Global Integrated
Strategy Leader for the
Alzheimer's franchise
at Roche


Daniel is the Global Integrated Strategy Leader for the Alzheimer's franchise at Roche. In this role, he acts as a core member of the molecule leadership team for late stage programs, and is the overall cross-functional lead of the commercial, medical and access teams. Daniel has previously held various roles in a range of therapeutic areas across the Roche portfolio in global, regional and country settings, and enjoys working at the intersection of technology, people and society. Prior to Roche, Daniel worked in biotech finance and technology commercialisation, having started his career in life sciences research where he achieved a Ph.D. in personalised healthcare."



Dr Chris Edgar

Chief Scientific Officer,
Cogstate

Dr. Chris Edgar has an extensive background in the application of clinical outcome assessments (COAs) in drug development and has worked in the pharmaceutical industry for the past 20 years. He is the former scientific director of Cognitive Drug Research Ltd. developers of CDR System, one of the earliest computerized cognitive test systems to be widely employed in clinical trials. Chris also has a background in COA management and rater training delivery with Bracket/UBC; and CNS/neuroscience clinical trial design and outcomes research with Roche, and as an independent consultant. Chris is a psychologist with expertise in clinical trials methodology, COA implementation, and related regulatory science topics. Chris's research seeks to carefully define and apply clinical endpoints to answer key questions throughout clinical development and product life-cycles.



Phyllis Ferrell

Vice President of the global Alzheimer's team for Eli Lilly and Company


Phyllis Ferrell is the Vice President of the global Alzheimer's team for Eli Lilly and Company. She and her team are responsible for the late-stage development and global registration of several treatments targeted for patients with Alzheimer's disease. She has been with Eli Lilly for more than 20 years and has held many leadership roles throughout the organisation. She has led efforts in sales, marketing, alliance management, strategy, Six Sigma and corporate financial planning. She is also a member of the Indiana Chapter of the Healthcare Businesswomen's Association and was recognised with their Rising Star Award in 2014. She is on the Boards of Directors for the Indiana Chapter of the Alzheimer's Association and the Stanford Associate Board of Governors; and is a founding member of Women Against Alzheimer's.



Franca Gatto

Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada

Franca Gatto is the Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada, a position she has held since September 2017. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Franca and her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of \$70M over five years to support key components of the strategy. Prior to joining the Public Health Agency, Franca gained over 25 years of experience in providing strategic policy and communications advice to decision-makers in the federal Health Portfolio, primarily at Health Canada.



Joyce Grey

Deputy Director
of Development,
Alzheimer Scotland


Joyce joined Alzheimer Scotland in January 2010 as Deputy Director of Development and leads on major projects that have attracted international interest e.g. Dementia Dog. Joyce has a BA in Business and Enterprise and IPD Diploma in Training Management, in addition to over 30 years experience in the health and social care sector. She started her career as a Psychiatric Nurse, but had the opportunity to join the voluntary sector in the early nineties and has since worked with young people excluded from main stream education, managed Carers Centres where she developed one of the first young carers services in the Scotland. Also before joining Alzheimer Scotland she worked on developing new and innovative services for people with learning disabilities. In her current role she drives the design innovation programme at Alzheimer Scotland pioneering the use of creativity to help build collaborative user driven service innovation.



Dr Katarzyna Hess-Wiktor

CEO and co-founder of
Minnity

Katarzyna Hess-Wiktor is the CEO and co-founder of Minnity, a startup with a mission to help people in need of care live dignified and meaningful lives. Currently, Minnity's person-centered digital tools help elderly care staff in Sweden and France improve their competencies through accessible digital learning and intuitive coordination. Katarzyna holds a PhD in Psychology from the Jagiellonian University in Krakow, Poland, and has worked for over 16 years in training and training management, 10 of which in training related to dementia care. Awarded Female Founder of the Year 2017 at the Sweden Demo Day and Ambassador of Polish Innovation 2020 by the PLUGin Foundation. Katarzyna is also a board member at the Swedish-Polish Chamber of Commerce, part of the steering group at WAZA, the network for Polish innovators and entrepreneurs in Sweden, and an active member of the World Young Leaders in Dementia network.



Professor Ha Thi Thanh Huong

Professor,
International
University, Vietnam
National University


Due to a family history of multiple members with mental disorders, Huong became intrigued in how the brain works, what molecules drive its functions and how they change when it gets dysregulated. During college research, Huong worked on identifying molecular markers and utilizing them in devising diagnostic tests. Following graduation, she further pursued this interest by working at the Oxford University Clinical Research Unit and investigating peripheral blood markers of HIV associated neurological disorders (HAND) using molecular biotechnology. At Stanford University, her PhD research was focused on understanding the molecular system related to autism and cellular and network deficits underlying epilepsy. Huong also created an efficient gene delivery technology and a universal brain tissue culture platform for research and drug discovery applications. Upon coming back to Vietnam and joining the International University as a lecturer, she established the Brain Health Lab and pursues several research projects.



Liam Kaufman

CEO and cofounder of
WinterLight Labs

Liam Kaufman is the CEO and cofounder of WinterLight Labs, which develops digital biomarkers to quantify cognitive impairment and mental health using speech and machine learning. Liam has authored multiple peer-reviewed scientific publications in neuroscience, cognitive neurology and human-computer interaction. In 2012 Liam launched Understoodit, a classroom polling app that was acquired in 2013 by EventMobi.



Dr Jeffrey Kaye

Layton Professor of Neurology and Biomedical Engineering at Oregon Health and Science University (OHSU)


Dr. Kaye is the Layton Professor of Neurology and Biomedical Engineering at Oregon Health and Science University (OHSU). He directs ORCATECH (the Oregon Center for Aging and Technology), ORCASTRAIT (Oregon Roybal Center for Care Support Translational Research Advantaged by Integrating Technology), and the NIA-Layton Aging and Alzheimer's Disease Research Center at OHSU. He leads or has led several longitudinal studies on aging and clinical trials including: Intelligent Systems for Detection of Aging Changes (ISAAC), the ORCATECH Life Laboratory, Ambient Independence Measures for Guiding Care Transitions, and the Collaborative Aging Research using Technology (CART) Initiative studies, all using pervasive computing and sensing technologies for assessment and interventions. He is listed in Best Doctors in America. He serves on many national and international panels and boards in the fields of geriatrics, neurology and technology. He is an author of over 400 scientific publications and holds several major grant awards from federal agencies, national foundations and industrial sponsors.



Dr Seb Kohler

Associate professor and a principal investigator, Alzheimer Center Limburg at Maastricht University Medical Center+

Seb is an associate professor at Department of Psychiatry and Neuropsychology and a principal investigator at the School for Mental Health and Neuroscience and the Alzheimer Center Limburg at Maastricht University Medical Center+. He leads the research line Neuroepidemiology, which specializes in research into risk and protective factors for cognitive decline and dementia and its translation into public health. Seb's group developed the LIBRA prevention score and eHealth tools, which are used in several ongoing prevention studies. He is a member of the Management Board of The Maastricht Study, a deep-phenotyping cohort of 9,000 individuals, and co-PI of the 25-year follow-up Maastricht Ageing Study. He co-leads the FINGER-NL trial, a 2-year multidomain lifestyle intervention program to promote brain health in older adults, which is part of the World Wide FINGER network, starting recruitment in Summer 2021.



Dr Lampros Kourtis

Consultant, Digital Health Innovation


Lampros is a scientist-entrepreneur working with Gates Ventures and ADDF on supporting technology initiatives in Alzheimer Disease and related dementias. Currently, Lampros is a Managing Director at Circadic, a digital health solutions provider, where he advocates for continuous, passive micro-symptom monitoring in Neurodegenerative Diseases. He is a partner at Velocity Partners, a micro-VC firm investing in early stage Healthtech startups. Previously, he cofounded venture -backed biotech startups Hyalex Orthopaedics, Biomimedica and Enzyquest and led them from concept to clinical application. Lampros maintains an Adjunct Professor position at Tufts School of Medicine. He holds a PhD from Stanford University and a BEng from Aristoteles University. He is a co-inventor in over 30 patents in the fields of biomaterials, medical devices and methods.



Dr Ivan Koychev

Clinical academic psychiatrist, University of Oxford

Ivan Koychev is a clinical academic psychiatrist at the University of Oxford with a focus on the development of treatments for neurodegenerative disorders. His research experience spans the key components of neuroscience clinical trial methodology: conduct of proof-of-concept (PoC) biomarker-based clinical trials in surrogate populations, testing of repurposed compounds, development of stratification and efficacy biomarkers and creation of infrastructure for large-scale stratified recruitment into preclinical dementia experimental medicine studies and clinical trials. He has a particular interest in the development of scalable biomarkers for the detection of preclinical Alzheimer's disease using digital technologies, blood biomarkers and longitudinal health data. Clinically, he works as a Consultant Neuropsychiatrist focusing on the assessment and management of patients with neuropsychiatric presentations in acute medical settings."



Dr Louise Lafortune

Senior research associate, University of Cambridge


Louise’s research seeks to develop a body of evidence to help older people retain independence and quality of life in their communities. Her works involve understanding the drivers of poor physical and mental health and inequalities in older age; identifying priorities for action by engaging with communities; evaluating interventions using routine data sources and tailored data collection; and building capacity for evidence-based public health policy and practice. Her current work includes projects on the use of routinely collected data to improve health in disadvantaged communities and a long-standing research programme aimed at developing the evidence base for Age Friendly and Dementia Community initiatives. Louise holds a dual PhD in Public Health and a background that includes nine years of industry engagement in clinical trials, health economics and outcomes research.



Clare Lucas

Dementia Policy Lead, UK Government

Clare works on dementia policy at the Department of Health and Social Care. Clare joined the Department in November 2020. Prior to her current role Clare worked in policy and campaigning roles at various UK disability charities.



Dr Jennifer Lynch

NIHR Knowledge Mobilisation Research Fellow, University of Hertfordshire


Dr Lynch is a Senior Research Fellow and NIHR Knowledge Mobilisation Research Fellow (2018-2021) in the Centre for Research in Public Health and Community Care (CRIPACC). Her research focuses on support provided to older people living in the community with complex health and social care needs, particularly involving technology-enabled care. As an NIHR Knowledge Mobilisation Research Fellow, Jennifer works with local authorities as they embed assistive technology into their social care offer and tackle challenges of sustainability, scale-up and spread. Her fellowship is concerned with developing knowledge mobilisation capacity by considering how different forms of knowledge and diverse perspectives can be brought together to catalyse change in complex systems. Dr Lynch is a former case study lead on the Wellcome Trust funded Studies in Co-creating Assisted Living Solutions (SCALS): www.scals.org through which the NASSS framework for planning and evaluating the sustainable implementation of health and care technologies was developed. "



Dr Hussein Manji

Global Head, J&J Science for Minds

Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT's Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in



peer-reviewed journals, including Science and Nature Neuroscience. He is an Honorary Fellow at Oxford University and Visiting Professor at Duke University, and previously served as Chief of the Laboratory of Molecular Pathophysiology at the NIH as well as Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.



Professor Cath Mummery

Consultant neurologist, and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery


Cath Mummery is a consultant neurologist, and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery. She is head of clinical trials at the Dementia Research Centre, University College London and has been chief investigator on over 20 early phase drug trials of potential disease modifying agents, including the ground-breaking platform trial DIAN-TU in presymptomatic individuals at risk of familial AD, and a first-in-human antisense oligonucleotide study, targeting MAPT to reduce tau in AD. She has a particular interest in early phase studies and genetic therapies, and in the psychological impact of trial participation. She sits on a number of advisory boards for potential disease modifying agents and for dementia service development. She is deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to the conduct of early phase trials in neurodegeneration.



Professor Chris Nugent

Head of the School of Computing, Ulster University

Chris is currently the Head of the School of Computing at Ulster University and leads the Pervasive Computing Research Centre. His research addresses the themes of the development and evaluation of technologies to support pervasive healthcare within smart environments. Specifically, this has involved research in the topics of mobile based reminding solutions, activity recognition and behaviour modelling and more recently technology adoption modelling. He currently serves as the Program Chair for the Technology Professional Interest Area of the Alzheimer's Association. Since 2008 he has served as the Associate Editor for the Editorial Board of the IEEE Engineering Medicine and Biology Conference, Healthcare Information Systems Theme.



Brad O'Connor

Managing Director
and Chief Executive
Officer, Cogstate

Brad O'Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. He has responsibility for Cogstate's overall strategic direction and day-to-day operations. Cogstate is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.



Foteini Orfaniotou

Group Digital Health
Leader Neuroscience
and Rare Diseases,
Roche


Foteini Orfaniotou is leading the Neuroscience and Rare Disease Digital Health team in the Product Development Medical Affairs organization. Her team leverages technologies to advance patient outcomes. Working cross-functionally, the focus is to implement solutions in the clinical practice setting that will advance early patient identification, disease monitoring and capturing outcomes that will inform clinical decisions and access to care. Foteini is a neuroscientist by training and her passion is to leverage technologies to advance care to patients with neurological diseases.



Professor Martin Orrell

Director of the
Institute of Mental
Health

Professor Martin Orrell is Director of the Institute of Mental Health, a partnership between the University of Nottingham and Nottinghamshire Healthcare NHS Foundation. He has led both the INDUCT and DISTINCT European networks on dementia care and technology comprising around 30 PhD students across 8 countries. He led the development and evaluation of Cognitive Stimulation Therapy for dementia which is now widely used in 30+ countries. In 2014 he was elected President of the European Association of Geriatric Psychiatry. He is Editor of the journal *Aging & Mental Health*. He is Chair of the Memory Services National Accreditation Panel (MSNAP) and was a member of the Prime Ministers Challenge on Dementia Research Group.



Dr Brian Patrick Smith

Director, Digital Health Strategy, Immunology & Neuroscience, Eli Lilly


Mr. Smith is currently the Director, Digital Health Strategy and External Innovation at Eli Lilly and Company. His primary responsibility is leading Lilly's new product planning efforts around digital opportunities in Alzheimer's disease, Pain and Immunology. He also leads the External Innovation efforts across all facets of Lilly's Digital Health Office. Prior to this role, Mr. Smith held several leadership roles in product management at Lilly, including Director roles with a focus in HCP and Consumer marketing and experience in marketing research. He has experience in several other disease states, including diabetes, growth disorders, osteoporosis and cardiovascular health. In 2006 he was named Lilly's Marketer of the Year. Prior to joining Lilly, he worked in finance and corporate development in the financial services industry. Mr. Smith graduated from Ohio University with a Bachelors in Business Administration, with majors in Finance, Management and Pre-Law, and a minor in Mathematics. He received his M.B.A from Indiana University's Kelley School of Business. He is a certified Six Sigma Black Belt.



Dr Peter Peumans

Life science technologies program lead, IMEC

Dr. Peumans holds a Ph.D. in electrical engineering from Princeton University, and a bachelor's and master's degree from the Katholieke Universiteit Leuven. Prior to joining imec, Dr. Peumans was a professor of electrical engineering at Stanford University. He is the recipient of an NSF CAREER award and a Belgian-American Educational Foundation honorary fellowship. He currently leads imec's life science technologies program.



**Professor
Vijayalakshmi
Ravindranath**

Professor, Centre for
Brain Research


Dr. Vijayalakshmi Ravindranath obtained her Ph.D from the University of Mysore in 1981. In 1986, after completing her post-doctoral training at the National Institutes of Health, USA, she joined the Department of Neurochemistry at National Institute of Mental Health and Neurosciences, (NIMHANS) Bangalore. In 1999, the Dept. of Biotechnology (DBT), Government of India sought her out to help establish the National Brain Research Centre (NBRC), an autonomous institution of DBT, Ministry of Science and Technology as a centre of excellence and to co-ordinate and network neuroscience research groups in the country. She continued as Founder Director, NBRC till May 2009, when she returned to Bangalore at the Indian Institute of Science (IISc) as Professor and Founder Chair of the newly created Centre for Neuroscience. She is currently Founder Director, Centre for Brain Research (CBR) at Indian Institute of Science. The newly established Centre for Brain Research is a unique public-private partnership between IISc (a public funded institution) and Pratiksha Trust (a philanthropy) that funds CBR. Research at CBR is focused on aging brain and a large, prospective longitudinal study of 10,000 ageing individuals has been initiated for the first time in India. In addition, she has received generous funding from Tata Trusts, which has paved the way for starting a longitudinal study in an urban cohort.



**Dr Ron
Riesenbach**

Vice president,
Innovation and CTO,
Baycrest Health
Sciences

Ron is VP Innovation and CTO of Baycrest Health Sciences. Ron is responsible for driving innovation at Baycrest including the introduction of new information systems, tools and digital services for clients, clinicians, researchers and educators. Among his responsibilities, Ron oversees the Baycrest Innovation Office and is leading a transformational initiative called Baycrest @ Home, which will lever emerging technologies to enable seniors to age successfully at home. In 2015, Ron helped found and was the inaugural Managing Director of the Centre for Aging and Brain Health Innovation (CABHI) – a \$124M, 5-year investment by the Governments of Ontario and Canada, community donors and industry partners."



Dr Julie Robillard

Assistant Professor
of Neurology at the
University of British
Columbia


Dr. Julie Robillard is an Assistant Professor of Neurology at the University of British Columbia and Scientist in Patient Experience at BC Children's and Women's Hospital. She is Chair of the Ethical, Legal and Social Implications Cross-cutting Program of the Canadian Consortium on Neurodegeneration in Aging and Vice-chair of the Technology and Dementia Professional Interest Area Executive Committee of the International Society to Advance Alzheimer's Research and Treatment, among other leadership roles. She leads the Neuroscience, Engagement and Smart Tech (NEST) lab where she brings her background in neuroscience and biomedical ethics to the evaluation and development of novel technologies to support brain health across the lifespan.



Professor Martin Rossor

NIHR National
Director for Dementia
Research, UCL Queen
Square Institute of
Neurology

Martin Rossor is the NIHR National Director for Dementia Research, Professor Emeritus, and Principal Research Associate at the UCL Queen Square Institute of Neurology. Following his training in clinical neurology at the National Hospital, Queen Square, Martin undertook primary research on the neurochemistry of degenerative dementia at the MRC Neurochemical Pharmacology Unit, Cambridge, before being appointed as Consultant Neurologist at St. Mary's Hospital London and the National Hospital in 1986. Martin was appointed as the Chairman of the Division of Neurology in 2002, after becoming Professor of Clinical Neurology. He established a specialist cognitive disorders clinic, which acts as a tertiary referral service for young onset and rare dementias. Martin's clinical research interests are in the degenerative dementias, particularly familial disease, and more recently in general cognitive impairment in systemic disease and multimorbidity. He established the Queen Square Dementia Research Centre and has served as the editor of the Journal of Neurology, Neurosurgery and Psychiatry, President of the Association of British Neurologists, Director of the NIHR Clinical Research Network for Dementia and Neurodegenerative diseases (DeNDRoN), and Director of the NIHR Queen Square Dementia Biomedical Research Unit. As part of the activities of DeNDRoN he established Join



Dementia Research (JDR), a national system for linking patients and public to research studies. He has served on numerous advisory boards and is currently associate member of the World Dementia Council, member of the UK Ministerial 2020 Dementia Programme Board, and Chairman of the Senate for the German Centre for Neurodegenerative Diseases (DZNE).



Professor Shekhar Saxena

Professor of the Practice of Global Mental Health at Harvard T H Chan School of Public Health


Dr Shekhar Saxena is Professor of the Practice of Global Mental Health at Harvard T H Chan School of Public Health. He is a psychiatrist by training and has worked previously at World Health Organization for 20 years including as the Director of the Department of Mental Health and Substance Abuse, Geneva from 2010 to 2018. His expertise includes providing advice and technical assistance to policy makers on prevention and management of mental, developmental, neurological and substance use disorders and suicide prevention. He led the WHO team for adoption of the first ever Mental Health Action Plan by the World Health Assembly in 2013. He also led the adoption of WHO Action Plan on Public Health Response to Dementia and its implementation.



Professor Philip Scheltens

Professor of cognitive neurology and director of the Alzheimer Center, Amsterdam University Medical Centers

Philip Scheltens is professor of cognitive neurology and director of the Alzheimer Center, Amsterdam University Medical Centers (The Netherlands) and member of the World Dementia Council. His main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national principal investigator for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 70 PhD theses have appeared since. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as the chair of its board."



Alyson Scurfield

CEO, TEC Services Association


Alyson Scurfield is a well-known visionary leader of service transformation, delivery and business development in the digital health and care sectors. She is currently Chief Executive of the TEC Services Association (TSA) and its subsidiary TEC Quality. As a key thought leader, Alyson has held a number of leadership positions, focusing on driving standards, quality improvement and workforce development both via TSA involvement in policy development and in setting sector service quality benchmarks in the UK and Europe with TEC Quality and UKAS. Passionate about how technology can transform care, she has led TSA's partnership work with Department of Health and Social Care and NHSx during the challenges of Covid-19. She is also driving the industry agenda for quality and continuous improvement with the TEC Quality standards framework to support population health. Her vision is for TSA to drive innovation to achieve integration of health, housing and social care.



Professor Sheung-Tak Cheng

Professor, The Education University of Hong Kong

Sheung-Tak Cheng is an internationally recognized authority in the field of gerontology in general and dementia care in particular. He has published over 160 articles and several high-level policy reports. He is an Emeritus Member and Issue Matter Specialist of the Global Council on Brain Health, and formerly an expert consultant to the United Nations Programme on Ageing. He is elected Fellow of the American Psychological Association (APA), the Association for Psychological Science, and the Gerontological Society of America. He was awarded the Outstanding International Psychologist Award and the Henry David Mentoring Award by APA's Division 52 in 2007 and 2015 respectively, and was honored in 2008 with the Certificate of Appreciation for Contributions as a Humanitarian Worker jointly presented by APA's Division 48 and Psychologists for Social Responsibility.



Dr Eric Siemers

President, Siemers
Integration


Eric Siemers has over 25 years of experience in clinical trials of neurodegenerative disease. His research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases. Dr Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company's Alzheimer's Disease Global Development Team, where he was responsible for the design and implementation of five large phase III clinical studies, in addition to playing a major collaborative role in two public-private partnership studies. Dr Siemers earned his medical degree from the Indiana University School of Medicine (US)."



Dr Heather Snyder

Vice president, Medical
& Scientific Relations
at the Alzheimer's
Association

Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer's Association®. In this role, she oversees Association initiatives that accelerate innovative Alzheimer's research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. To increase knowledge about prevention and risk reduction, Dr. Snyder serves on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.



Dr Ioannis Tarnanas

Chief Scientific Officer,
Altoida


Ioannis Tarnanas received his PhD in Neuroscience from Aristotle University of Thessaloniki, Greece. Tarnanas pioneered virtual and augmented reality environments for everyday function monitoring since 2000. In 2005 he became involved in the first digital biomarker project in the world from Novartis AG, the smart exelon patch, approved by the FDA in 2013. Since then he has been a Novartis fellow focusing on using new technologies to understand the aging process and to establish prevention methods that decrease the risk of developing dementia or delay the onset of the disease. Currently Tarnanas is a Senior Fellow with the Global Brain Health Institute (GBHI), based in Trinity College Dublin. Dr Tarnanas's work on novel technologies for assessing and treating age-related cognitive function is of central strategic interest to GBHI and together they have the international outreach to scale up scientific, medical and technological discoveries of proven value through a truly global alumni network. Tarnanas recently created an accurate predictive tool based on cognitive and non-cognitive biomarkers of early onset dementia. The program, named Altoida's Neuro Motor Index (NMI), aims to spot the first neurological effects of Alzheimer's disease with 94% accuracy up to decades before symptoms appear.



Dr Pieter Visser

Clinical epidemiologist
at the Maastricht
University Medical
Centre and VU
University Medical
Center

Pieter Jelle Visser, MD, PhD, is a clinical epidemiologist at the Maastricht University Medical Centre and VU University Medical Center in the Netherlands and visiting professor at the Karolinska Institute in Stockholm, Sweden. His research focuses on the pathophysiology, diagnosis, prognosis and treatment of predementia Alzheimer's disease. He supervises the RADAR-AD clinical study on digital biomarkers in AD. In addition, he has coordinated projects on datasharing and data pooling such as the Netherlands Consortium of Dementia Cohorts, EMIF-AD and the Amyloid Biomarker Study.



George Vradenburg

Co-Chair of the
Davos Alzheimer's
Collaborative

George Vradenburg serves as Co-Chair of the Davos Alzheimer's Collaborative, a coalition focused on driving global scientific, business, policy and financial coordination in Alzheimer's preparedness, co-convened in January 2020 by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum. In this role, George provides general oversight and advocacy and works to ensure the Collaborative remains sustainable and action-oriented. George is the Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2), a disruptive and catalytic force committed to stopping Alzheimer's by 2020. In 2011, the United States Secretary of the Department of Health and Human Services named George to serve on the National Alzheimer's Advisory Council on Research, Care and Services for the first-of-its-kind National Alzheimer's Strategic Plan. George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2020 World Dementia Council
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

